Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane

Eriseld Krasniqi, Giacomo Barchiesi, Marco Mazzotta, Laura Pizzuti, Alice Villa, Maddalena Barba, Patrizia Vici

Research output: Contribution to journalArticlepeer-review

Abstract

RATIONALE: Within a rapidly expanding therapeutic armamentarium, the combination of everolimus (Eve) plus exemestane (Exe) utility needs to be reinstated in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC).

PATIENT CONCERNS: We herein report on a patient affected by HR+ HER2- MBC treated with radical surgery after neoadjuvant chemotherapy, who relapsed early on adjuvant tamoxifen, progressed rapidly on first line anastrozole, and failed treatment with third line capecitabine.

DIAGNOSES: Metastatic luminal breast cancer progressed under standard endocrine therapy and chemotherapy.

INTERVENTIONS: Third line with Eve plus Exe was given after chemotherapy.

OUTCOMES: Patient experienced a 5-year progression free interval.

LESSONS: Eve plus Exe remains a valid option in HR+HER2- MBC.

Original languageEnglish
Pages (from-to)e21211
JournalMedicine
Volume99
Issue number31
DOIs
Publication statusPublished - Jul 31 2020

Keywords

  • Androstadienes/administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms/diagnosis
  • Carcinoma, Lobular/diagnosis
  • Everolimus/administration & dosage
  • Female
  • Humans
  • Liver Neoplasms/diagnosis
  • Middle Aged
  • Premenopause
  • Progression-Free Survival

Fingerprint Dive into the research topics of 'Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane'. Together they form a unique fingerprint.

Cite this